– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...

BILLINGS - Staff from St. Vincent Healthcare met at their Regional Neuroscience Center for the grand opening of their brand new state-of-the-art Multiple Sclerosis Infusion Center. Doctors, patients ...

MILAN -- An investigational 10-minute subcutaneous injection of ocrelizumab (Ocrevus) was non-inferior to the established IV infusion formulation of the drug in multiple sclerosis (MS), the phase III ...

The rapid proliferation of high-efficacy disease-modifying therapies for multiple sclerosis (MS) has revolutionized the treatment landscape, yet significant gaps remain in how health systems organize ...

Multiple Sclerosis is a chronic disease in which the body attacks itself by mistake. Some people may never have symptoms, for others, MS can be debilitating; it's incurable, but medications can help ...

Multiple sclerosis (MS) is a disease that looks different in everyone who has it—and you may know more people who have it than you think. According to Thomas Shoemaker, MD, a RUSH neurologist and MS ...

Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune response. Copaxone and Glatopa mimic a protein in myelin to ...

Black patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) may respond differently to common MS treatment compared to their White peers, new research suggests. "The ...